Tag: Stock pick

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a modest gain. At the time of writing, the benchmark index is up 0.2% to 8,631.7 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:

Brightstar Resources Ltd (ASX: BTR)

The Brightstar Resources share price is down 4% to 41.7 cents. This appears to have been driven by the gold miner issuing almost 245 million new shares this morning. Last month, Brightstar Resources announced a strategic $180 million capital raising to fund a material increase in production. Brightstar’s managing director, Alex Rovira, said: “To emerge with all the equity funding required to build our Goldfields Hub, as well as a substantial budget that enables accelerated pre-development activities at Sandstone and to fully fund Sandstone to FID, is an amazing opportunity for Brightstar that enables us to maintain the momentum of de-risking our portfolio of advanced gold projects.”

EQ Resources Ltd (ASX: EQR)

The EQ Resources share price is down 6.5% to 29 cents. This is despite the tungsten producer releasing an investor presentation this morning. Within the presentation, management stated: “EQR is one of the largest producers of tungsten outside of restricted countries, with spot-priced offtake agreements in place, supplying Europe, North America and Asian markets.”

Novonix Ltd (ASX: NVX)

The Novonix share price is down almost 5% to 26.2 cents. This has been driven by news that the battery technology company’s NASDAQ-traded shares could be delisted due to its weak share price. It advised: “The notice states that, for the previous 30 consecutive business days, the closing bid price of the Company’s American Depositary Receipts (ADRs) listed on the Nasdaq has been below the minimum requirement of US$1.00 per ADR. In accordance with Nasdaq Listing Rules, the Company has 180 calendar days from the date of the notice to regain compliance (compliance period). To regain compliance, the closing bid price of the Company’s ADR’s must be at least US$1.00 per ADR for a minimum of 10 consecutive business days during the compliance period.”

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is down a further 2% to $125.40. This is despite there being no news out of the health imaging technology company. However, Pro Medicus’ shares have been under pressure this year amid concerns over AI disruption. This has seen the Pro Medicus share price lose over 40% of its value since the turn of the year.

The post Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today appeared first on The Motley Fool Australia.

More reading

• ASX All Ords gold stock lifts off on exploration success
• 2 ASX small-cap mining shares to sell: Experts
• Why New Hope, Pepper Money, Pro Medicus, and Reece shares are falling today
• Should you buy CSL and Pro Medicus shares today?
• 3 ASX growth shares that could benefit from the AI boom

Life360 Inc (ASX: 360) shares are charging higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) location-sharing software developer closed yesterday at $18.94. In early afternoon trade on Wednesday, shares are changing hands for $19.55 apiece, up 3.2%.

For some context, the ASX 200 is up 0.2% at this same time.

Despite today’s welcome outperformance, the ASX tech stock remains down a sharp 39.8% since the opening bell sounded on 2 January.

Among the headwinds, Life360 shares have been caught up in the broader tech stock sell-off amid investor concerns that artificial intelligence (AI) could replace many of the services these companies currently offer.

Which brings us back to our headline question.

Should you buy Life360 shares today?

Baker Young’s Toby Grimm recently ran his slide rule over Life360 shares (courtesy of The Bull).

“Life360 is a leading family safety and location sharing platform operating across the US, UK and Australia,” he said.

Life360 released its results for the full 2025 calendar year on 3 March. Commenting on those results, Grimm noted:

The company delivered better-than-expected full year results in 2025, highlighted by subscription revenue increasing 33%. Hardware remains an important long term growth option, as it helps lock users into paid subscriptions.

Despite reporting solid growth metrics for 2025, Life360 shares crashed 17.6% on 3 March.

But Grimm doesn’t believe investors should sell their shares. Explaining his hold recommendation, he concluded:

We believe the magnitude of the recent share price decline has been excessive given the strength across most of Life360’s core subscription business. Accordingly, we remain comfortable holding this high quality, fast growing and profitable company at current levels.

What’s the latest from the ASX 200 tech stock?

As mentioned, Life360 shares plunged a sharp 17.6% on the day the company reported its full-year results.

On top of the 33% year on year lift in revenue to US$489.5 million that Grimm pointed out above, sales came despite the company achieving 105% growth in its adjusted earnings before interest, taxes, depreciation and amortisation EBITDA to US$93.2 million.

Commenting on the results on the day, Life360 CEO Lauren Antonoff said, “For the first time in company history, we achieved annual net income, reflecting both the fundamental strength of our freemium model and the operating discipline we’ve built over the past several years.”

As for the rapid advancement of AI, Antonoff added:

We are deep into the transition to become an AI-first company. Organization-wide active AI adoption has grown to over 95%, accelerating our execution and expanding what’s possible for families on our platform.

We see AI as an opportunity to accelerate our path and deepen our moat. Our core use case is durable because it is anchored in real people moving through the physical world, generating data that further deepens our advantage.

The post Down 40% in 2026, should you buy the big dip in Life360 shares? appeared first on The Motley Fool Australia.

More reading

• Life360 and two ASX 200 shares for smart investors to buy
• Buy, hold, sell: Life360, Magellan, and QBE shares
• What are the best ASX 200 shares to consider buying for the next 5 years?
• $10,000 invested in Life360 shares at the start of March is now worth…
• Are 4DMedical and Life360 shares a buy, hold or sell after rocketing 10% yesterday?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Tuesday, as was widely expected, the Reserve Bank of Australia (RBA) delivered another blow to mortgage holders by increasing interest rates for the second month in a row.

The central bank lifted the cash rate by 25 basis points to 4.1% at March’s meeting.

The RBA explained:

A wide range of data over recent months have confirmed that inflationary pressures picked up materially in the second half of 2025. While part of the pick-up in inflation is assessed to reflect temporary factors, the Board judged that the labour market has tightened a little recently and capacity pressures are slightly greater than previously assessed. Developments in the Middle East remain highly uncertain, but under a wide range of possible scenarios could add to global and domestic inflation.

In light of these considerations, the Board judged that inflation is likely to remain above target for some time and that the risks have tilted further to the upside, including to inflation expectations. It was therefore appropriate to increase the cash rate target.

What’s next for interest rates?

Last year, the RBA changed its meeting schedule from monthly to eight times a year.

One of the months that doesn’t have a meeting is April, which means the central bank has a bit of time to observe economic data, run its numbers, and ultimately make its decision on where interest rates are going next.

At present, the RBA Rate Indicator, which is based on the ASX 30 Day Interbank Cash Rate Futures May 2026 contract, suggests that there is a good probability of a rate increase at the May meeting.

The RBA Rate Indicator currently sits at 57% in favour of an increase to 4.35%. If this proves accurate, it will mean three meetings in a row of hikes to interest rates, much to the dismay of borrowers.

Will the RBA hike?

Unfortunately, the economics team at Westpac Banking Corp (ASX: WBC) appears to believe that the market is onto something with its prediction.

Australia’s oldest bank believes the RBA will increase interest rates in May, before pausing at 4.35% for the foreseeable future.

Westpac’s senior economist, Mantas Vanagas, commented:

Domestically, focus was on the RBA – as anticipated, the central bank raised the cash rate by 25bp for the second time this year, bringing it to 4.10%. The narrow 5–4 vote in favour of tightening highlighted significant differences of opinion within the Monetary Policy Board, however, Governor Bullock clarified at the press conference that these differences concerned the timing of the hike, not the direction of policy. We continue to expect another interest rate increase in May, though it will likely depend on developments in the Middle East conflict.

After a rate hike in May, Westpac expects rates to stay at 4.35% until late 2027. It then expects rates to fall to 3.6% by March 2028.

The post Why the RBA could increase interest rates again in May appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• How many Westpac shares do I need to buy for a $10,000 annual passive income?
• 3 ASX dividend shares I’d buy instead of Westpac
• Here’s what Westpac says the RBA will do with interest rates next week
• Here’s what experts think will happen with the RBA interest rate this month

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Brainchip Holdings Ltd (ASX: BRN) shares have recouped their earlier intraday losses, trading flat at 14 cents apiece during the Wednesday lunch hour.

This sees shares in the S&P/ASX 300 Index (ASX: XKO) artificial intelligence (AI) stock down about 43% over the past 12 months.

Nuix Ltd (ASX: NXL) shares have had an even tougher year.

Shares in the ASX 300 investigative analytics and intelligence software provider are down 1% at the time of writing, changing hands for $1.53 each. This puts the Nuix share price down 53.5% over 12 months.

For some context, the ASX 300 has gained 9.9% since this time last year.

And if Peak Asset Management’s Niv Dagan has it right, Nuix and Brainchip shares could have further to fall (courtesy of The Bull).

Time to sell Brainchip shares?

“Brainchip is a commercial producer of neuromorphic artificial intelligence (AI),” said Dagan, who has a sell recommendation on Brainchip shares.

If you’re not familiar with what that means, the company’s neuromorphic processor, Akida, is intended to mimic the human brain and keep machine learning local to the chip, independent of the cloud.

“The company operates across Australia, the US and Europe and had a market capitalisation of about $349.17 million during trading on March 12,” Dagan said.

Explaining his sell recommendation, Dagan said:

The broader AI hardware landscape is increasingly dominated by big players, such as Nvidia. The AI sector is intensively competitive. The company substantially lifted revenue in full year 2025 but reported a loss from continuing operations after tax.

Full-year revenue of US$1.9 million was up 374% from 2024. The loss from continuing operations came in at US$20.4 million.

“Brainchip shares have fallen from 24.5 cents on October 9, 2025, to trade at 14 cents on March 12. Other stocks appeal more at this stage of the cycle,” Dagan concluded.

Also on the selling block

Apart from Brainchip shares, Dagan also recommends selling Nuix.

“Nuix is an investigative analytics software provider,” he said. “It enables customers to process and search large data sets of unstructured information, including emails, documents and communications records.”

Despite the sizeable one-year losses, Nuix shares are up 12.1% since the company reported its half-year results on 23 February.

Which could make today a good day to think about taking some profits, according to Dagan. He noted:

The company earns most of its revenue from licence and maintenance fees. Revenue of $121.2 million in the first half of fiscal year 2026 was up 15.2% on the prior corresponding period. Annualised contract value of $234.4 million was up 8.4%.

Investors may want to consider taking a profit as we believe gains are priced in following the half year result. We see limited scope for upside amid increasing competition.

The post Sell alert! Why this expert is calling time on Nuix and Brainchip shares appeared first on The Motley Fool Australia.

More reading

• What are analysts saying about ResMed, Downer, and Nuix shares?
• Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares
• Up 41% last week, why this buy rated ASX 300 stock is tipped to leap another 69%
• Why Brainchip, Fortescue, Qantas, and Westpac shares are dropping today
• Why Bapcor, Brainchip, Coles, and Harvey Norman shares are dropping today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Nuix. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is on track to record a small gain on Wednesday. In afternoon trade, the benchmark index is up 0.2% to 8,629.7 points.

Four ASX shares that are rising more than most today are listed below. Here’s why they are climbing:

Electro Optic Systems Holdings Ltd (ASX: EOS)

The EOS share price is up 7% to $9.52. Investors have been buying this defence and space company’s shares after a major sell-off on Tuesday. That sell-off was triggered by news that the company’s CEO, Dr Andreas Schwer, was given approval to sell 2.5 million EOS shares on-market following the exercise of options that were granted under a long-term incentive plan. Some investors may believe the selling was an overreaction, especially after its CEO committed to retain a shareholding well above the minimum levels required under its recently announced shareholding policy.

Humm Group Ltd (ASX: HUM)

The Humm share price is up 5.5% to 69.2 cents. This is despite the financial services company revealing that the Takeovers Panel made a declaration of unacceptable circumstances. It said: “[T]he Panel considered that the following statements in Humm’s 17 December 2025 announcement of the conditional, non-binding indicative offer from Credit Corp Group Limited (Credit Corp) to acquire control of Humm (Credit Corp Proposal) were misleading and contrary to an efficient, competitive and informed market.” The Panel advised that it is still considering whether it should make final orders.

New Hope Corporation Ltd (ASX: NHC)

The New Hope share price is up 6% to $5.27. This may have been driven by a broker note out of Bell Potter this morning. In response to its half-year results, Bell Potter has upgraded the coal miner’s shares to a hold rating with a $4.50 price target. It said: “We upgrade to a Hold recommendation and apply a 5% premium to our sum of the parts valuation with energy security concerns exacerbated by recent geopolitical issues. NHC’s low-cost operations will continue to underpin margins through the coal price cycle, funding capital expenditure commitments and supporting shareholder returns.”

Sims Ltd (ASX: SGM)

The Sims share price is up 8% to $20.37. This morning, this global leader in metal recycling and the provision of circular solutions for technology released a trading update. Sims revealed that it expects FY 2026 underlying EBIT to be in the range of $350 million to $400 million. This will be at least double the underlying EBIT of $174.9 million that the company reported in FY 2025.

The post Why EOS, Humm, New Hope, and Sims shares are storming higher today appeared first on The Motley Fool Australia.

More reading

• EOS shares rebound after yesterday’s 16% plunge as insiders move to cash out
• Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares
• Guess which ASX 200 stock is jumping 17% on strong FY26 guidance
• What is this broker saying about New Hope Group shares?
• Sims flags stronger FY26 earnings on robust metals and tech demand

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are many exchange-traded funds (ETFs) on the ASX for Australian investors to choose from.

If I were putting money into the market today, these are a few Vanguard ETFs I’d be happy to buy for my portfolio.

Vanguard MSCI Index International Shares ETF (ASX: VGS)

The VGS ETF could be a great pick for Australian investors wanting global exposure.

It provides access to a wide range of developed-market companies, particularly in the United States, but also across Europe and other major economies.

What I like about it is that it captures many of the world’s most dominant businesses in one place. These are companies with global reach, strong margins, and the ability to keep growing regardless of what’s happening in any single country.

Rather than trying to pick which global winners will outperform, this ETF lets you own a broad slice of them.

It also reduces reliance on the Australian market, which traditionally is heavily concentrated in banks and miners. And while that concentration is good when the banks and miners are charging higher, it can be bad when the cycle turns. As a result, the VGS ETF’s diversification alone could make it a valuable building block in a portfolio.

Vanguard FTSE Asia Ex-Japan Shares Index ETF (ASX: VAE)

The VAE ETF adds an entirely different dimension.

It provides exposure to some of the world’s fastest-growing economies. This includes countries like China, India, and Taiwan.

These markets don’t always move in line with the US or Australia. That can create periods of volatility, but it also opens the door to growth that isn’t available in more mature economies.

What stands out to me is the long-term story. Rising middle classes, increasing digital adoption, and ongoing industrial development are powerful forces that could drive growth for many years.

It’s not the smoothest ride, but that’s part of the trade-off when investing in developing regions.

Vanguard Diversified High Growth Index ETF (ASX: VDHG)

Lastly, the VDHG ETF also takes a different approach.

Instead of targeting a specific region, it bundles together a diversified portfolio of growth assets, including Australian shares and international equities.

To me, this is one of the simplest ways to invest.

It’s essentially a ready-made portfolio that is designed for long-term growth. There’s no need to constantly rebalance or decide how much to allocate to each market. That’s handled within the fund.

What I find appealing is how it combines convenience with diversification. For investors who don’t want to spend time managing multiple positions, it offers a straightforward way to stay invested in global growth.

Foolish Takeaway

I think ETFs are one of the easiest ways to invest in the market. But with so much choice, it can be hard to decide which funds to buy.

The VGS, VAE, and VDHG ETFs each offer a slightly different way to invest, but all provide broad exposure and long-term growth potential.

For me, they’re simple options I’d be happy to buy and hold.

The post Why I’d buy VGS and these Vanguard ETFs right now appeared first on The Motley Fool Australia.

More reading

• New to investing? Start with ASX ETFs and quality ASX stocks
• The ASX ETFs to buy for growth, income, and diversification
• 5 fantastic ASX ETFs to buy and hold for five years
• Why I think these Vanguard ETFs could outperform the ASX 200
• How I’d start building an ASX retirement portfolio today

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Perpetual Ltd (ASX: PPT) had some big news this week, announcing the sale of its wealth management business to Bain Capital Private Equity for $500 million.

The analyst team at Macquarie have run the ruler over the sale, and has upgraded their price target for Perpetual shares as a result.

Major deal

We’ll get to that later; let’s first look at what was announced.

Perpetual will sell the Perpetual Wealth business to Bain for $500 million, plus a potential $50 million payment depending on the performance of the business.

Perpetual Chief Executive Officer Bernard Reilly said regarding the sale:

Following a thorough sale process, we believe we have achieved the right outcome for our shareholders, clients and people, and one that reflects Wealth Management’s longstanding reputation as a premium provider of high net worth advisory, fiduciary, philanthropic and not-for-profit offerings in the Australian market. “This is a pivotal step in our strategy to simplify and transform Perpetual. Following completion, Perpetual will have a stronger balance sheet and more simplified business, focused on two core businesses, asset management and corporate trustee services, while also enhancing its ability to invest for future growth and deliver improved shareholder returns over the longer term. We believe we have found the right owner for the Wealth Management business to help it continue to grow and deliver high quality products and services to its clients.

The money raised will be used to retire debt and support investment in Perpetual’s asset management and corporate trust divisions.

Perpetual shares looking cheap

The Macquarie team said the sale, which followed a 12-month process, was conducted at a multiple which appeared reasonable.

They noted that Perpetual must overcome several regulatory hurdles to complete the transaction and that separating the wealth business would be complex.

They added:

However, Perpetual expects no ‘material’ stranded costs post-completion, reflecting an effective carve-out while generating revenue to offset any lingering costs during this process.

Macquarie raised its price target on Perpetual from $23.85 to $24.60 on the back of the deal. This compares to Perpetual’s current share price of $16.02.

They added:

Despite continued outflows, we reiterate our Outperform rating, with the Wealth sale to simplify the business and unwind some of the some of the parts discount, while we see scope for further cost out above current plans with Perpetual’s cost-to-income ahead of global peers.  

Perpetual is also expected to pay a 7% dividend yield this financial year. Perpetual was valued at $1.86 billion at the close of trade on Wednesday.   

The post How high does Macquarie think this ASX 200 stock will go after its wealth sale? appeared first on The Motley Fool Australia.

More reading

• Why Lifestyle Communities, Perpetual, Reliance Worldwide, and Woodside shares are rising today
• This ASX financial stock just struck a $500 million deal
• Perpetual sells Wealth Management business to Bain Capital for $500m
• 32 ASX shares about to go ex-dividend
• Perpetual posts higher earnings and tight cost control for 1H26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ResMed Inc (ASX: RMD) shares are marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company closed yesterday trading for $32.63. At the time of writing, shares are changing hands for $32.91 apiece, up 0.9%.

For some context, the ASX 200 is up 0.1% at this same time.

ResMed shares have broadly been trending lower since the ASX 200 healthcare stock notched a new all-time closing high of $45.41 on 21 August.

Over the past 12 months, shares are down 5.2%. Though that doesn’t include the 24.6 cents a share in unfranked dividends ResMed has paid out over the full year.

Which brings us back to our headline question.

Should you buy ResMed shares today?

Securities Vault’s Nathan Lodge recently ran his slide rule over the ASX 200 healthcare stock (courtesy of The Bull).

“ResMed remains a global leader in sleep apnoea devices and digital health monitoring,” Lodge noted.

And ResMed shares look well-placed to deliver long-term growth.

“Structural demand drivers, including ageing populations, increasing diagnosis rates and broader awareness of sleep health, continue to support long term growth,” Lodge said.

But he’s not ready to pull the trigger just yet.

Explaining his hold recommendation on ResMed shares, Lodge concluded:

However, a strong share price recovery following concerns about the impact of weight loss drugs on sleep apnoea treatment appears to leave much of the near-term optimism priced into the stock.

While the company’s fundamentals remain robust, the valuation reflects its market leadership and growth outlook. Investors may prefer to retain existing positions, while awaiting further earnings expansion, or more attractive entry points.

What’s the latest from the ASX 200 healthcare stock?

ResMed reported its second-quarter results (Q2 FY 2026) on 30 January.

Highlights included an 11% year-on-year increase in revenue to $1.42 billion (up 9% in constant currency). And net income of $392.6 million was up 14% from Q2 FY 2025.

The company reported sales growth across most of its operating regions. Sales in the United States, Canada, and Latin America increased 11% year on year, while sales in Europe and Asia were up 6% (in constant currency).

Commenting on the results, ResMed CEO Mick Farrell said:

These results reflect strong ongoing demand for our market-leading sleep and respiratory care devices, as well as the growing impact of our digital health ecosystem that spans more than 140 countries.

Looking ahead, Farrell added:

As we move into the second half of fiscal year 2026, we will continue to invest in innovation to scale our digital health capabilities and expand global access to life-saving care, while delivering sustainable, profitable growth.

ResMed shares closed up 3.1% on the day of the result announcement.

The post With global populations ageing, are ResMed shares a good buy today? appeared first on The Motley Fool Australia.

More reading

• Why Cochlear and ResMed shares could be strong buys
• Where to invest $5,000 in Australian shares for the rest of 2026
• Life360 and two ASX 200 shares for smart investors to buy
• What are analysts saying about ResMed, Downer, and Nuix shares?
• Why I think DroneShield and 2 more ASX shares are buys

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Shaw and Partners have run the ruler over AML3D Ltd (ASX: AL3) shares after a major contract win, and they like what they see.

The broker is predicting more than 100% upside for the ASX technology company’s shares, which we’ll get to shortly.

Major new contract win

Firstly, let’s look at what they announced this week.

AML3D said they had received a $9.9 million order for four Arcemy X 3D printing systems from US shipbuilder Newport News Shipbuilding, which is a division of HII which is the largest US military shipbuilder.

AML3D chief executive officer Sean Ebert said it was a major milestone for the company.

The step change in the size and value of this HII ARCEMY order is very much reflective of the strong and growing demand signals that underpin AML3D’s continued expansion into the U.S. defense market. It is also a strong endorsement of our U.S. ‘Scale up’ strategy which included establishing our U.S. technology Center in Stow Ohio and our plans to invest $12 million to expand our U.S. production capabilities. Not only do we expect to see a continued growth in U.S. defense orders we are also looking to continue to expand into other sectors. We have already successfully supplied ARCEMY technology to the Tennessee Valley Authority, the largest public utility in the U.S., and are targeting growth across the U.S. Marine, Energy, Aerospace and Oil & Gas sectors. In addition, we are seeing the emergence of early-stage demand in our UK and European markets that is similar to the demand signals that are driving our success in the U.S.

Shares looking cheap

Shaw and Partners said the new order supports their projection for FY27 revenue at AML3D of $30 million.

They added:

AL3 is set for growth with U.S. reshoring initiatives, strengthened by key partnerships including the U.S. Navy and Boeing.

And they said more announcements were likely:

AL3 has been in discussions with the US Navy/BlueForge Alliance around an A$23mn “Phase 2” expansion of additive manufacturing capacity in the Navy’s supply chain. This is likely to involve 10 ARCEMY systems and could be framed by a “take or pay” agreement with the Navy to supply printed components. The contract depends on appropriation of funding under the National Defense and Authorization Act FY26. We believe funds may be made available for this arrangement over the next month catalysing AL3 to make an announcement at that time.

Shaw has a price target of 40 cents on AML3D shares, compared with just 17 cents currently. AML3D was valued at $93.9 million at the close of trade on Tuesday.

The post This ASX technology stock could more than double: broker appeared first on The Motley Fool Australia.

More reading

• Guess which ASX defence stock is jumping 22% on US military order
• This under the radar ASX defence company could more than double in value, a broker says

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are racing higher in Wednesday morning trade. At the time of writing the biopharmaceutical company’s shares are up 8% to $12.58 a piece.

The uptick now means the shares are 11% higher for the year-to-date and have recovered some losses seen during the sharp selloff throughout 2025.

Telix shares are now 54% lower than this time last year.

What happened to Telix shares?

Telix shares crashed in early 2026 after the company’s Q4 FY25 results disappointed investors. In late January, Telix reported that it had achieved the lower end of its guidance, but investors weren’t pleased, and the 2025 share sell-off accelerated.

It’s just one of several significant headwinds that the company has faced over the past six months, including slow or delayed regulatory approvals for some of its key radiopharmaceutical products.

In mid-February, Telix shares finally reached the bottom and started rebounding. The uptick started when the company announced that it had filed a key regulatory approval in Europe.

Investors were pleased with the announcement and it looks like sentiment has finally started rebounding.

The good news has continued through March with several announcements about the company’s growth and development plans.

The company released its Part 1 results from its global Phase 3 ProstACT study of TLX591-Tx, its novel prostate cancer therapy last week. The results were encouraging, and showed that the therapy demonstrates an acceptable and manageable safety profile, with no new safety signals and sustained tumour uptake across patients.

This week, Telix announced it has resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), a brain cancer imaging candidate. Telix’s resubmission includes new data addressing the FDA’s previous requests. The new submission is expected to be enough to gain US Food and Drug Administration (FDA) approval.

And why are Telix shares storming higher today?

There hasn’t been any new price-sensitive information out of Telix today to explain the current share price hike. But it’s likely that a positive sentiment swing is now flowing through to investors, causing an increase in buying activity.

Has the tide finally turned for Telix?

Telix shares are now widely considered oversold and undervalued.

Analysts are very bullish on where the share price can go from here. TradingView data shows that all 16 analysts have a buy or strong buy rating on the stock. And the expectation among all of them is that the share price will fly higher over the next 12 months.

Some expect the shares to climb 92% to $23.97, but others are even more optimistic and expect the share price to rocket to $31.59 a piece over the next 12 months. That implies an enormous 154% upside, at the time of writing.

The post Why are Telix shares racing 8% higher today? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 3 ASX shares tipped to race up to 188% higher
• Why Regis Resources, Strike Energy, Telix, and Virgin Australia shares are falling today
• Telix shares drop despite promising US FDA update
• Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.